413 related articles for article (PubMed ID: 34761360)
1. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
[TBL] [Abstract][Full Text] [Related]
2. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):69-89. PubMed ID: 34658008
[TBL] [Abstract][Full Text] [Related]
3. Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.
Sutherland CS; Hudson P; Mitchell S; Paracha N
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):39-67. PubMed ID: 34907515
[TBL] [Abstract][Full Text] [Related]
4. Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.
Aponte Ribero V; Martí Y; Batson S; Mitchell S; Gorni K; Gusset N; Oskoui M; Servais L; Sutherland CS
Neurology; 2023 Nov; 101(21):e2103-e2113. PubMed ID: 37813581
[TBL] [Abstract][Full Text] [Related]
5. Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy.
Yang M; Awano H; Tanaka S; Toro W; Zhang S; Dabbous O; Igarashi A
Adv Ther; 2022 May; 39(5):1915-1958. PubMed ID: 35307799
[TBL] [Abstract][Full Text] [Related]
6. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
7. Costs of Illness of Spinal Muscular Atrophy: A Systematic Review.
Landfeldt E; Pechmann A; McMillan HJ; Lochmüller H; Sejersen T
Appl Health Econ Health Policy; 2021 Jul; 19(4):501-520. PubMed ID: 33576939
[TBL] [Abstract][Full Text] [Related]
8. Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review.
Landfeldt E; Abner S; Pechmann A; Sejersen T; McMillan HJ; Lochmüller H; Kirschner J
Pharmacoeconomics; 2023 Mar; 41(3):275-293. PubMed ID: 36515815
[TBL] [Abstract][Full Text] [Related]
9. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
10. Spinal muscular atrophy: survival pattern and functional status.
Chung BH; Wong VC; Ip P
Pediatrics; 2004 Nov; 114(5):e548-53. PubMed ID: 15492357
[TBL] [Abstract][Full Text] [Related]
11. Disease burden of spinal muscular atrophy in Germany.
Klug C; Schreiber-Katz O; Thiele S; Schorling E; Zowe J; Reilich P; Walter MC; Nagels KH
Orphanet J Rare Dis; 2016 May; 11(1):58. PubMed ID: 27145956
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
13. Health care costs and resource use of managing hemophilia A: A targeted literature review.
Chen Y; Cheng SJ; Thornhill T; Solari P; Sullivan SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):647-658. PubMed ID: 37276036
[No Abstract] [Full Text] [Related]
14. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy.
Cattinari MG; de Lemus M; Tizzano E
Orphanet J Rare Dis; 2024 Feb; 19(1):76. PubMed ID: 38373977
[TBL] [Abstract][Full Text] [Related]
15. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy.
Chambers GM; Settumba SN; Carey KA; Cairns A; Menezes MP; Ryan M; Farrar MA
Neurology; 2020 Jul; 95(1):e1-e10. PubMed ID: 32513788
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
17. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
[TBL] [Abstract][Full Text] [Related]
18. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments.
Salort-Campana E; Solé G; Magot A; Tard C; Noury JB; Behin A; De La Cruz E; Boyer F; Lefeuvre C; Masingue M; Debergé L; Finet A; Brison M; Spinazzi M; Pegat A; Sacconi S; Malfatti E; Choumert A; Bellance R; Bedat-Millet AL; Feasson L; Vuillerot C; Jacquin-Piques A; Michaud M; Pereon Y; Stojkovic T; Laforêt P; Attarian S; Cintas P
Orphanet J Rare Dis; 2024 Jan; 19(1):24. PubMed ID: 38268028
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
